BIOMARIN PHARMACEUTICAL INC 8-K

What Happened

• BioMarin Pharmaceutical Inc. announced financial results for the fourth quarter ended December 31, 2025. The company issued a press release dated February 23, 2026, and attached that release to this Form 8-K as Exhibit 99.1. The filing was furnished under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Press release date: February 23, 2026 (attached as Exhibit 99.1).
• Reporting period: Fourth quarter ended December 31, 2025.
• Filing items: Item 2.02 (results of operations) and Item 9.01 (exhibits); Inline XBRL cover page included as Exhibit 104.
• Legal note: The press release and information in this Form 8-K are furnished, not “filed,” and therefore are not subject to certain liabilities under the Exchange Act and the Securities Act as described in the filing.
• Form signed by G. Eric Davis, Executive VP and Chief Legal Officer, on February 23, 2026.

Why It Matters

• This 8-K signals that BioMarin has released its latest quarterly earnings and related financial information — important for investors tracking revenue, earnings, guidance, or operational updates.
• Because the detailed figures are in the attached press release (Exhibit 99.1) rather than in the body of the 8-K, investors should read that press release to see specific revenue, net income/loss, EPS, and any guidance or management commentary.
• The “furnished, not filed” designation limits certain legal exposures for the company but does not affect the availability of the information; the Inline XBRL exhibit helps analysts and tools extract machine-readable financial tags.